Polypeptide Group Ag · SIX:PPGN
Polypeptide — Jefferies Healthcare Conference 2023
11 slides from Polypeptide's conference presentation, Nov 15, 2023
Slide 1: PolyPeptide Group AG – Jefferies Healthcare Conference 2023
PolyPeptide Group AG (SIX: PPGN) Jefferies Healthcare Conference 2023 Juan-José Gonzalez, CEO London, 15 November 2023 GLOBAL SUPPORT FOR A QUALITY SOLUTION
Slide 2: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by PolyPeptide Group AG (“PolyPeptide" and together with its subsidiaries, "we", "us" or the "Group"). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports availab
Slide 3: We operate in one of the most attractive CDMO markets
We operate in one of the most attractive CDMO markets Peptides approved as therapeutic agents1 ~1,000 peptide drug projects (synthetic and recombinant) o/w ~330 in clinical development, with ~60 in phase III2 Diabetes & obesity 40 Hormonal disorders 22 Main therapeutical 16 areas 14 11 Autoimmune di
Slide 4: The market has momentum, driven by GLP-1 programs
The maket has momentum, driven by GLP-1 programs Peptides therapeutics market (USD m)1 • 2023 to 2026 CAGR for GLP-1 of ~18%1, driven by new drug approvals and promising phase III results 80000 CAGR ~11% • Rich peptide-based GLP-1 project pipeline for the 70000 mid-term, incl. injectables and orals
Slide 5: PolyPeptide is a leader in the outsourced peptide API market
PolyPeptide is a leader in the outsourced peptide API market Over 70 years' experience Custom projects pipeline with of manufacturing API’s 226 active projects a focused CDMO for peptides and oligos supporting complex molecules 1/ Manufacture of over 3 of all approved peptide-based API’s 6 Multi-sit
Slide 6: We are close to our customers – “start here, stay here”
We are close to our customers – “start here, stay here” Competitive advantages Multi-site network infrastructure Strong development capabilities Culture of flexibility and responsiveness GLOBAL SUPPORT FOR A QUALITY SOLUTION 6
Slide 7: In the first half of 2023, we posted 29% underlying growth
In the first half of 2023, we posted 29% underlying growth1 Custom Projects € m Contract Manufacturing € m 100 Generics & Cosmetics € m +37% +24% 26 7 2 50 57 58 41 47 +23% 13 16 0 H1 2022 H1 2023 H1 2022 H1 2023 H1 2022 H1 2023 Associated with coronavirus pandemic. 1 Excluding revenue associated wi
Slide 8: Our revenue mix shows transformational progress
Our revenue mix shows transformational progress Mix by therapeutic area1 Mix by customer type1 Metabolic 65% Oncologic Large pharma 43% 41% Other Biotech 28% Covid-related Other pharma & academia H1 2022 H1 2023 H1 2022 H1 2023 1 Approximate revenue mix as at 30 June 2022 and 30 June 2023. GLOBAL SU
Slide 9: We are well positioned with a leading development pipeline
We are well positioned with a leading development pipeline Active custom projects by # of projects / phase Revenue mix by therapeutic areas1 226 181 EUR 131.8 million Metabolic Oncologic Gastro 30 31 Phase III Cardio & Neuro H1 2021 H1 2023 Other 1 Approximate revenue mix as at 30 June 2023. GLOBAL
Slide 10: Financial guidance for 2023
Financial guidance for 2023 Clear focus for H2 2023 • Mid to high single-digit percentage revenue growth vs 2022 • Meet customer demand and deliver • At the lower end of that range, EBITDA around on planned growth in H2 2023 break-even, excluding the EUR 9.5 million • Continue implementation of inve
Slide 11: Q&A
Q&A
PolyPeptide Group — Jefferies Healthcare Conference 2023 on 6ix